Elsevier Editorial System(tm) for Journal of Hepatology

Manuscript Draft

Manuscript Number: JHEPAT-D-18-00233R2

Title: Prediction of Early Recurrence after Surgical Resection of Hepatocellular Carcinoma: An International Collaborative Study

Article Type: Original Article

Keywords: hepatocellular carcinoma; recurrence; resection

Corresponding Author: Professor Philip James Johnson,

Corresponding Author's Institution: University of Liverpool

First Author: Anthony Chan

Order of Authors: Anthony Chan; Jianhong Zhong; Sarah Berhane; Hidenori Toyoda; Alessandro Cucchetti; KeQing Shi; Toshifumi Tada; Charing Chong; Bang-De Xiang; Le-Qun Li; Paul Lai; Vincenzo Mazzaferro; Marta García-Fiñana; Masatoshi Kudo; Takashi Kumada; Sasan Roayaie; Philip James Johnson

Abstract: Background and aims
Resection is the most widely used potentially-curative treatment for patients with early hepatocellular carcinoma (HCC). However, recurrence within 2 years occurs in 30-50% of patients, being the major cause of mortality. Here, we describe two models, both based on widely available clinical data, which permit risk of early recurrence to be assessed before and after resection.

Methods
3903 patients undergoing surgical resection with curative intent from 6 different centres were recruited. Two models for early recurrence, one using preoperative and one using pre and post-operative data were built and internally validated in the Hong Kong cohort. The models were then externally validated in European, Chinese and US cohorts. Two online calculators were developed to permit easy clinical application.

Results
Multivariable analysis identified male, gender, large tumour size, multinodular tumour, high Albumin-Bilirubin (ALBI) grade and high serum AFP as the key parameters related to early recurrence. Using these variables, a pre-operative model (ERASL-pre) gave three risk strata for recurrence free survival (RFS) in the entire cohort - low risk: 2-year RFS 64.8%, intermediate risk: 2-year RFS 42.5% and high risk: 2-year RFS 20.7%. Median survival in each stratum was similar between centres and the discrimination between the three strata was enhanced in the post-operative model (ERASL-post) which included 'microvascular invasion'.

Conclusions
Statistical models, that can predict the risk of early HCC recurrence after resection, have been developed, extensively validated and shown to be applicable in the international setting. Such models will be valuable

in guiding surveillance follow-up and in the design of post-resection adjuvant therapy trials.

Response to Reviewers:

Agreed and amended accordingly.

*Cover Letter

Philip J Johnson, MD, FRCP,
Professor in Translational Oncology,
Department of Molecular & Clinical Cancer Medicine,
2/F The Sherrington Building,
Ashton Street,
Liverpool L69 3GE
Tel: +44 151 795 8410
Philip.Johnson@liverpool.ac.uk

The Editor
The Journal of Hepatology

22nd August 2018

Dear Dr. Sangro,

Re: Prediction of early recurrence after surgical resection of hepatocellular carcinoma: an international collaborative study. JHEPAT-D-18-00233
Anthony WH Chan, Jianhong Zhong, Sarah Berhane, Hidenori Toyoda et al.

Thank you for your e mail of 22nd August and we are delighted to hear that the above mentioned paper has now been accepted for publication in the Journal of Hepatology.

We have addressed the minor remaining issues as requested and have re-submitted the manuscript.

Best wishes.

Yours sincerely,

Philip J Johnson MD, FRCP
Philip.Johnson@liverpool.ac.uk

*Submission checklist

Journal of Hepatology

Revised Submission Checklist

This form must be completed and submitted for all revised manuscripts. Without this form the manuscript will be returned to the corresponding author for completion.

Corresponding Author:	Philip Johnson
Manuscript Number:	JHEPAT-D-18-00233R2

Below, provide the page number(s) or figure legend(s) where the information can be located. Please make sure that all the information requested below is present in the manuscript.

		Completed, or reported on page(s) or figure legend(s):
1)	**Submission**	
a)	Title page: COI, Financial support, Authors' contributions, keywords.	Y
b)	Structured abstract and lay summary	Y
c)	All tables and figures included, numbered correctly, with legends (p value and statistical test)	Y
d)	Supplementary data included in a single, separate word file	Y
e)	A detailed point by point response to reviewers comments and changes highlighted in text	Y
f)	All authors to complete and upload an ICMJE conflict of interest form.	Y
g)	Graphical abstract	Y
2)	**Materials and methods**	
a)	Completed the CTAT form for all reagents and resource to be added to supplementary material	Completed
b)	Identify the source and authentication of cell lines	Not applicable
c)	Identify animal species, number of animals used, strain, sex and age.	Not applicable
d)	For animal studies include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.	Not applicable
e)	For qPCR data provide information according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines	Not applicable
3)	**Human subjects**	
a)	Identify the committee(s) approving the study protocol.	Page 7
b)	Include a statement confirming that informed consent was obtained from all subjects.	Page 7
		Not applicable

c) For randomized studies report the clinical trial registration number (at ClinicalTrials.gov or equivalent).

d) For phase II and III randomized controlled trials:

a. Please refer to the CONSORT statement and submit the CONSORT checklist with your submission. — Not applicable

b. Include the study protocol and statistical plan — Not applicable

e) Identify the inclusion/exclusion criteria in the selection process for the patients included in the study — Page 7

4) Statistics

a) State what statistical tests were completed and why — Page 9-11

b) Explain the sample size and how this size provides an adequate power to detect a pre-specified effect size. — Not applicable

5) Data deposition (Provide accession codes for deposited data)

a) When using public databases:

a. Identify the source and include a valid link — Not applicable

b. When using databases that require permission, include a statement confirming that permission was obtained — Not applicable

b) Data deposition in a public repository is mandatory for:

a. Protein, DNA and RNA sequences — Not applicable

b. Microarray data — Not applicable

Deposition is strongly recommended for many other datasets for which structured public repositories exist — Not applicable

Journal of Hepatology

CTAT methods

Tables for a "Complete, Transparent, Accurate and Timely account" (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as 'Supplementary CTAT Table'
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
Not applicable				

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
Not applicable					

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
Not applicable						

1.4 Sequence based reagents

Name	Sequence	Supplier
Not applicable		

1.5 Biological samples

Description	Source	Identifier
Not applicable		

1.6 Deposited data

Name of repository	Identifier	Link
Not applicable		

1.7 Software

Software name	Manufacturer	Version
R version	R Foundation for Statistical Computing, Vienna, Austria	3.2.5
Stata	StataCorp, Texas, USA	SE 14.2

1.8 Other (e.g. drugs, proteins, vectors etc.)

Not applicable		

1.9 Please provide the details of the corresponding methods author for the manuscript:

All statistical queries was referred to:
Sarah Berhane (University of Liverpool)
Marta Garcia-Finana (University of Liverpool)

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Not applicable

***Detailed Response to Reviewers**

Reviewer #2:
I thank the authors for the thorough revision of their manuscript.

I only have some minor comments left:

1. Page 10, beta-coefficients has been changed to beta-estimates, but page 11 there remains beta-coefficients.

Agreed and amended accordingly (page 9 line 21).

2. "Prognostic performance" is too vague: it reflects several components. For instance, Harrell's c index and Gönen-Heller K and Royston-Sauerbrei measures, are parameter that mainly reflect the prognostic separation, or discrimination. But calibration (how predicted probabilities match observed ones) is another valid aspect of the performance of a prognostic score. So I would suggest being more precise in the terminology, and use discrimination when referring to c, K or R2_D, or better explain in what sense "performance" is intended here.

Agreed and amended accordingly (page 10, line 10-17; page 14, line 1-8).

Reviewer #3: The authors had considered reviewers remarks and the paper is improved. It is a large serie of HCC with a simple score that could be prospectively tested in others work so it merits to be published.

We are grateful to the reviewer for his positive response.

Prediction of Early Recurrence after Surgical Resection of Hepatocellular Carcinoma: An International Collaborative Study

Anthony W.H. Chan[1], Jianhong Zhong[2], Sarah Berhane[3], Hidenori Toyoda[4], Alessandro Cucchetti[5], KeQing Shi[6], Toshifumi Tada[4], Charing C.N. Chong[1], Bang-De Xiang[2], Le-Qun Li[2], Paul B.S. Lai[1], Vincenzo Mazzaferro[7], Marta García-Fiñana[8], Masatoshi Kudo[9], Takashi Kumada[4], Sasan Roayaie[10], Philip J Johnson[3]

Addresses and affiliations

1. *State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Department of Anatomical & Cellular Pathology, and Department of Surgery, The Chinese University of Hong Kong*
2. *Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China*
3. *Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK*
4. *Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki, Gifu, 503-8052, Japan*
5. *Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy*
6. *Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China*
7. *University of Milan and Gastrointestinal Surgery and Liver Transplantation Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy*
8. *Department of Biostatistics, University of Liverpool, Liverpool, UK*
9. *Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan*
10. *Liver Cancer Program, White Plains Hospital – Montefiore Health System, White Plains, NY, United States.*

Running head: Early recurrence of hepatocellular carcinoma

Keywords: hepatocellular carcinoma; recurrence; resection

Corresponding Author:
Philip J Johnson, Professor in Translational Oncology, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd floor Sherrington Building, Ashton Street, Liverpool L69 3GE, UK
Tel: 0151 795 8410
E-mail: Philip.Johnson@liverpool.ac.uk

List of where and when the study has been presented in part elsewhere:
International Liver Cancer Association meeting, Seoul, South Korea, 2017

Conflicts of interest: none

Word count: 5542

Number of figures and tables: 3 figures and 5 tables

Acknowledgements of research support for the study: SB and MGF acknowledges support from the UK EPSRC grant EP/N014499/1

Author contributions:
Concept and design: PJJ, AWHC
Data collection: JZ, HD, AC, KS, TT, CCNC, BDX, LQL, PBSL, VM, MK, TK, SR
Statistical analysis: SB, AWHC, MGF
Writing of article: all authors

ABSTRACT

Background and aims

Resection is the most widely used potentially-curative treatment for patients with early hepatocellular carcinoma (HCC). However, recurrence within 2 years occurs in 30-50% of patients, being the major cause of mortality. Here, we describe two models, both based on widely available clinical data, which permit risk of early recurrence to be assessed before and after resection.

Methods

3903 patients undergoing surgical resection with curative intent from 6 different centres were recruited. Two models for early recurrence, one using preoperative and one using pre and post-operative data were built and internally validated in the Hong Kong cohort. The models were then externally validated in European, Chinese and US cohorts. Two online calculators were developed to permit easy clinical application.

Results

Multivariable analysis identified male, gender, large tumour size, multinodular tumour, high Albumin-Bilirubin (ALBI) grade and high serum AFP as the key parameters related to early recurrence. Using these variables, a pre-operative model (ERASL-pre) gave three risk strata for recurrence free survival (RFS) in the entire cohort - low risk: 2-year RFS 64.8%, intermediate risk: 2-year RFS 42.5% and high risk: 2-year RFS 20.7%. Median survival in each stratum was similar between centres and the discrimination between the three strata was enhanced in the post–operative model (ERASL-post) which included ‘microvascular invasion’.

Conclusions

Statistical models, that can predict the risk of early HCC recurrence after resection, have been developed, extensively validated and shown to be applicable in the international setting. Such models will be valuable in guiding surveillance follow-up and in the design of post-resection adjuvant therapy trials.

LAY SUMMARY

The most effective treatment of cancer that starts in the liver (hepatocellular carcinoma) is surgical removal of the tumour but there is often recurrence. In this large international study, we develop a statistical method that allows clinicians to estimate the risk of recurrence in an individual patient. This facility enhances communication with the patient about the likely success of the treatment and will help in designing clinical trials that aim to find drugs that decrease the risk of recurrence.

Introduction

Worldwide, hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death.(1) There is a wide variety of therapeutic options for HCC patients, depending on tumour burden, liver function and performance status.(2) Potentially curative therapy recommended for those patients with very early/early stage tumour (Barcelona Clinic Liver Cancer [BCLC] 0/A) consists of surgical resection, liver transplantation or local ablation. Due to scarcity of donor organs, surgical resection and ablation are the mainstay of curative treatment options in Asian-Pacific countries, which account for three quarters of all new patients globally.(1) Surgical resection provides better clinical outcome than local ablation particularly among patients with well-preserved hepatic function.(3, 4)

However, tumour recurrence is a major post-operative complication and is generally classified into early or late recurrence by using 2 years as the cut-off.(5, 6) Early recurrence (i.e. within 2 years of resection) accounts for more than 70% of tumour recurrence and is assumed to represent 'true recurrence' whereas after this period "recurrences" are assumed to be largely accounted for by 'de novo' tumours.(7) The 2-year recurrence-free survival (RFS) is about 50% and 30% among and those with BCLC 0 or A tumours, respectively.(7-9) Identification of patients after potentially curative surgery who are at high risk of recurrence allows clinicians to provide appropriate surveillance so as to detect recurrent HCC at its earliest stage, when curative therapy may still be feasible.

Curative therapy offers much more favourable long-term survival than palliative therapy among patients with recurrent HCC.(3, 10, 11) Patients at high risk of early recurrence are

potential candidates for clinical trials of adjuvant therapy although there is no standard of care for adjuvant therapy for surgically treated HCC patients. (6, 12) (13) (14) (15)

Currently, there is no consensus as to the optimal tool for risk stratification and this may partially contribute to failure of clinical trials of adjuvant therapy due to suboptimal patient selection. Except for the American Joint Committee on Cancer (AJCC) Tumour-Node-Metastasis (TNM), the majority of HCC staging systems are not derived from surgically managed patients. Their prognostic performances on classifying post-operative early recurrence have not been fully evaluated. A few models including the Singapore Liver Cancer Recurrence (SLICER) score, the Korean model, Surgery-Specific Cancer of the Liver Italian Program (SS-CLIP), have been developed specifically to detect tumour recurrence after surgical resection but none of them have been externally validated.(8, 9, 16). Moreover, microvascular invasion is an important component of AJCC TNM, SLICER, SS-CLIP and Korean models, but only can be evaluated pathologically in the resected specimen after operation. A prognostic model that only requires parameters that are available pre-operatively may help surgeons to better select surgical candidates.

In this study, we employed large cohorts from different countries to develop and validate prognostic models for surgically treated HCC patients based on readily accessible clinical and pathological parameters on order to predict early recurrence. Two models were developed: One included parameters available before surgery so as to allow prediction of early recurrence pre-operatively, and a second that included parameters available only after resection to give a more accurate prediction.

Patients and methods

This analysis was reported according to the TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) guidelines(17).

Patients

In this international retrospective cohort study, a total of 3903 surgically treated HCC patients from 6 centres in different countries were accrued. These centres comprise Hong Kong (the Chinese University of Hong Kong), mainland China (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou; Affiliated Tumour Hospital of Guangxi Medical University, Nanning), Italy (S.Orsola-Malpighi Hospital, University of Bologna and Gastrointestinal Surgery, Istituto Nazionale Tumori, Milan), Japan (Ogaki Municipal Hospital), and the United States (personal experience Sasan Roayaie, New York). All centres fulfilled ethical requirements (including informed consent) according to local practice and it is our understanding that such studies do not require formal protocol approval. Inclusion requirements were that the patients underwent surgical resection of HCC with curative intent. Patients who underwent resection for tumour rupture were excluded. All resections were undertaken after the year 2000 except for the Japanese cohort where patients were recruited between 1990 and 2014. There was no statistically significant difference in survival or recurrence rates between those treated before and after the year 2000. Table 1 summarizes baseline characteristics of the patient cohorts. Patients with missing data were excluded from the analysis.

The pre-operative and post-operative ERASL models were built on the Hong Kong dataset (dates 2001-2012) and then internally validated on a similar population from Hong Kong (dates 2013-2015). We then validated the models externally on datasets from mainland China,

Italy, Japan and the United States. The criteria for surgical resection in Eastern centres (Hong Kong, mainland China and Japan) included: good liver function indicated by a 15-min ICG retention rate of <30% (Hong Kong and Japan) or Child-Pugh A with presence of appropriate residual liver volume determined by volumetric computed tomography and/or magnetic resonance imaging (mainland China); a single HCC, or not more than 3 HCCs, located in the same segment; less than 85 years of age (<75 years in Wenzhou); and absence of extrahepatic metastasis. In Italy(18), and the United States, a personalized approach was undertaken based on multidisciplinary discussion.

All clinical and laboratory parameters were collected and reviewed from patients' records. The Albumin-Bilirubin (ALBI) score was computed by the formula, −0.085× (albumin g/l) + 0.66×log (bilirubin μmol/l).(19) Patients were stratified into three groups according to previously described cut-offs resulting in three grades: ALBI grade 1 (≤−2.60), grade 2 (>−2.60 to −1.39) and grade 3 (>−1.39).(19) Macrovascular invasion was defined as vascular invasion of large vessels detectable radiologically, whereas microvascular invasion was vascular invasion of small vessels only identifiable histologically. There was no microvascular invasion data available in the Nanning cohort, hence this cohort was used for validation of the pre-operative model only. Patients in the Hong Kong cohort were classified according to 7th edition of AJCC TNM, Korean model (including 5 parameters: gender, tumour volume, microvascular invasion, serum albumin and platelet count) and SLICER score (using 8 parameters: symptomatic, cirrhotic background, Child-Pugh grade, surgical resection margin distance, tumour size, tumour number, vascular invasion, and preoperative serum alpha fetoprotein AFP).(8, 9) After tumour resection, all patients were followed up according to institutional practice including clinical assessment serum AFP 6-monthly and ultrasound or contrast-enhanced computed tomography every 6 to 12 months. RFS was

defined as the time from date of curative surgery to the time of recurrence. Patients with no recurrent disease were censored at the last time at which they were known to be recurrence free. Those dying within 90 days of surgery were not excluded from the analysis. The 90-day mortality rate was 0.6% (Hong Kong derivation cohort), 0.7% (Hong Kong internal validation cohort), 1.5% (Japan), 7.7% (the United States), 0% (Wenzhou, China), 0.9% (Nanning, China) and 2.7% (Italy).

Statistical analyses

All statistical analyses were performed in R version 3.2.5 (R Foundation for Statistical Computing, Vienna, Austria) or Stata/SE 14.2 (StataCorp, Texas, USA). Continuous variables were reported as mean (with standard deviation [SD]) or median (with interquartile range [IQR]), the latter for variables with highly skewed distributions. Categorical variables were presented as percentages. We constructed two models to predict early recurrence using the derivation cohort. One model, the pre-operative model, was based on clinicopathological parameters available before surgery; the second, the post-operative model, was developed on all available parameters. Clinicopathological parameters that were shown to be potentially relevant (with $p<0.2$ in the univariable Cox regression) were considered for generating the multivariable Cox model. The multivariable Cox regression model was built by stepwise backward selection of variables significant at the 10% level. A number of potentially clinically plausible interactions were also included in the selection. Model β-estimates were used to compute hazard ratios and calculate the risk score for prediction of early recurrence. The risk score was a weighted sum of those significant parameters, of which the weights were β-estimates~~coefficients~~ from the multivariable Cox regression analysis. The proportional hazards assumption of the models was tested by examining the plots of scaled Schoenfeld residuals against time for each variable in the models. By applying previously reported cut-

offs (50th and 85th centile) to the score (20), three risk groups (low, intermediate and high) were generated. Kaplan-Meier (KM) survival curves according to the risk groups were plotted for each of the derivation and validation sets. Median RFS, hazard ratio (HR), and percentage RFS at 2 years were also calculated for each risk group.

Model discrimination was assessed via the "regression on the prognostic index (PI)" approach (20), also known as the "calibration slope". The regression coefficient on the risk score in the validation sets was estimated and compared to that of the derivation set, which is by construction exactly 1. If the validation set coefficients equals to 1, <1 or >1, they reflect as good as, poorer or better discrimination respectively in relation to the derivation set.

~~Prognostic performance~~ Model discrimination ~~of the models~~ in the derivation and validation sets was also measured by the Harrell's c-index, Gönen & Heller's K, Royston-Sauerbrei's R^2_D and time dependent receiver operating characteristic curve (tdAUC).(20-22) Cumulative/dynamic tdAUC was evaluated because we aimed to discriminate between individuals experiencing recurrence and those recurrence-free prior to 2 years. ~~The prognostic~~Discriminatory performance of our newly established models was~~ere~~ also compared to AJCC TNM, the Korean model and the SLICER in the Hong Kong derivation and validation sets.

Models were calibrated using calibration plots and comparing model-predicted versus observed survival curves.

Calibration plots were applied to the derivation and validation sets. Estimates of predicted versus observed values were generated via bootstrapping (with 200 resampling). In order to

obtain a continuous calibration plot for a specific survival time, regression-spline interpolations(23, 24) were used to generate a continuous observed survival probability. The resulting plot was also "optimism-corrected" by a method described by Harrell et al (25).

Model-predicted mean survival curves were generated by applying fractional polynomial regression to approximate the log baseline cumulative hazard function as a smooth function of time (20). Model-predicted versus KM estimates was then plotted according to each risk group in the derivation and validation sets.

Results

Construction of the model predicting early recurrence

In the derivation cohort, 451 patients receiving curative surgery between 2001 and 2012 were recruited after excluding 44 patients who were complicated by tumour rupture before operation. There were only two patients with missing data on at least one of the variables. ALBI grade 2 and ALBI grade 3 were group together due to low sample size in the latter. One hundred and sixty-two patients (35.9%) developed recurrence within 2 years of surgery. Among 18 clinicopathological parameters analysed, 12 were found to be potentially relevant with $p<0.2$ in the univariable Cox regression analysis (Supplementary table 1). Four of these, namely positive resection margin, ALT, ALP and INR, had to be excluded because they were not available in all of the external validation cohorts. Two parameters, namely (intraoperative blood loss and microvascular invasion) were only recorded after the operation and hence excluded in the multivariable analysis for establishing the pre-operative model, whereas all 8 parameters were employed for building the post-operative model. By the stepwise multivariable analysis, independent parameters were identified for both models (Table 2). We

did not detect any significant violation of the proportional hazard assumption, assessed by scaled Schoenfeld residuals on functions of time.

The pre-operative model, **E**arly **R**ecurrence **A**fter **S**urgery for **L**iver tumour (ERASL-pre) score, was constructed; its formula shown in Table 2. The RFS of an individual patient with a particular ERASL-pre score can be estimated by applying a previously described formula (Supplementary table 2)(26). Using 2.558 and 3.521 as the cut-off values of the ERASL-pre score (which correspond to the 50^{th} and 85^{th} centile of the score in the derivation cohort, respectively), three prognostically distinct groups were stratified (derivation cohort): low-risk (2-year RFS: 76.3%), intermediate-risk (2-year RFS: 57.4%; P<0.001 in comparison to low-risk) and high-risk (2-year RFS: 29.5%; P<0.001 in comparison to intermediate-risk) (Table 3; Fig.1A). The ERASL-pre score could identify 15% of patients at particularly high-risk (70.5%) of early recurrence. For routine clinical application a simple online calculator that takes the variables from the model(s) and returns the ERASL scores, the risk group and the recurrence free survival likelihood at any time between 1 and 24 months after resection for the individual patient was developed and is available at: https://jscalc.io/calc/Fu3bREKIInObXCtj

Similarly, the post-operative model, ERASL-post, was built according to the formula for score shown in Table 2. As in ERASL-pre, the RFS of an individual patient with a particular ERASL-post score can be estimated (Supplementary Table 2). Using the 50^{th} and 85^{th} centiles of the ERASL-post scores in the derivation cohort, 2.332 and 3.445 respectively, as cut-off values, three prognostically distinct groups were classified (derivation cohort): low-risk (2-year RFS: 80.9%), intermediate-risk (2-year RFS: 50.9%; P<0.001 in comparison to low-risk)

and high-risk (2-year RFS: 30.0%; P<0.001 in comparison to intermediate-risk) (Table 4; Fig. 2A). The ERASL-post score was able to identify 15% of patients at high-risk (70.0%) of early recurrence.

Internal and external validation of the ERASL models

Both ERASL models were first validated in an internal validation cohort, which was composed of 130 patients with HCC receiving curative surgery between 2013 and 2015 in Hong Kong. There was no missing data in the internal validation set. By using the cut-off values established in the derivation cohort (2.558 and 3.521), the ERASL-pre model categorized patients into low-risk (2-year RFS: 77.1%), intermediate-risk (2-year RFS: 67.5%; P=0.313 in comparison to low-risk) and high-risk (2-year RFS: 19.4%; P<0.001 in comparison to intermediate-risk) groups (Table 3; Fig. 1B). Similarly, patients from the independent external validation cohorts from five centres (after exclusion of patients with incomplete data on predictor parameters), Japan (n=582), the United States (n=548); Wenzhou, China (n=98); Nanning, China (n=1198); and Italy (n=742), could be also categorized into three separate risk groups by the ERASL-pre model (Fig. 1C-F) (Table 3). Likewise, the ERASL-post model subdivided patients from the internal and external validation cohorts into three distinct risk groups (Fig. 2C-F) (Table 4).

Assessing model discrimination ~~and prognostic performance~~

Overall, the regression coefficient on the ERASL-pre and post scores showed good discrimination relative to the derivation set across validation cohorts (coefficient figures ranging from 0.70 to 1.21) although discrimination was less good in the Italian cohort (ERASL-pre: 0.59, ERASL-post: 0.65).

Similarly the ~~prognostic~~ discriminatory performance of the models was compared via Harrell's c-index, Gönen & Heller's K, Royston-Sauerbrei's R^2_D and tdAUC as shown in Table 5. Both models showed similar performance in the derivation and internal validation sets. In the external validation cohorts, good discrimination was also observed, although there was a slight deterioration in the measurement figures, which was most pronounced in the Italian cohort.

The ~~prognostic~~ discriminatory performance of both ERASL models exceeded those of AJCC TNM, the Korean model and the SLICER score in predicting early recurrence (Table 5). By including microvascular invasion, ERASL-post showed a better performance than ERASL-pre.

Calibration

The calibration plots showed an overall good agreement between the predictions made by the ERASL pre and ERASL post models and observed outcome in the Hong Kong derivation and internal validation sets (Figure 3A-F). This was also the case for the external validation sets (Supplementary figure 1 A-H).

Plots of KM estimates versus ERASL-pre predicted survival curves were overall very similar (Supplementary figures 2 [A-F]), with the exception of the Chinese cohort, the lowest risk groups of the Japanese, U.S. and Italian cohorts where the ERASL-pre model overestimated RFS. In the ERASL-post model, there was also an overall agreement between KM estimates and model-predicted survival probabilities (Supplementary figures 3 [A-F]) with the exception of model overestimation of RFS in the low risk categories of Japan and Italy. Nevertheless, despite some of discrepancies between predicted and KM estimates in some of

the risk groups, the stratification of each of the cohorts into three groups according to risk was maintained.

KM survival plots according for the ERASL-pre and post risk groups involving the entire cohort are shown in Supplementary figure 4.

Discussion

Two models (ERASL-pre and ERASL-post) that enable risk assessment of early recurrence before and after resection have been derived and validated in a large international multicentre study of surgically-treated HCC patients. Although they were derived from a hepatitis B prevalent region (Hong Kong), their application was generalizable to regions with predominant hepatitis C (Japan and Italy) or mixed aetiologies (the United States). They were capable of stratifying patients into three groups with discrete risk profiles. Using the ERASL-pre model, the high-risk group consisted of 13.1% of the patients among the entire cohort but accounted for 79.3% of those who developed early recurrence, whereas the low-risk and intermediate-risk groups comprised of 46.1% and 40.8% of patients but only 35.2% and 57.5% of those who developed early recurrence, respectively (Supplementary Fig. 4). Correspondingly, the ERASL-post also identified a high-risk group comprising 12.3% of patients among the entire cohort with 73.9% chance of early recurrence (Supplementary Fig. 4). Both models are clinically relevant because they allow the identification of a small, but potentially manageable, portion of patients at high risk in the development of early recurrence. Although it may not be considered appropriate to exclude those patients at high-risk of early recurrence from curative surgery, more intensive surveillance might be offered and they would be candidates for clinical trials of adjuvant therapy. The ERASL models are also reliable as they are the first models designed to predict early recurrence that have been

externally validated in different geographic regions and with different etiological factors. Despite, a minor degree of discrepancy between predicted and KM estimates (Supplementary figure 2 and 3), the stratification of each of the cohorts into three groups according to risk was maintained. Although the ERASL-pre model is the first to be applicable solely on the basis of pre-treatment parameters, it still appears to outperform existing models which require additional postoperatively acquired variables. It may also help surgeons to identify those surgical candidates at high risk of early recurrence before operation. Furthermore, the models only require simple, readily available clinicopathological parameters.

Vascular invasion, in particular microvascular invasion, is a well-known independent prognostic factor associated with more advanced tumour stage, tumour progression and poorer clinical outcome.(27) Microvascular invasion is the single parameter shared by ERASL-post, SLICER, SS-CLIP and Korean models.(8, 9, 16) It is also an essential component in the AJCC TNM system. The incidence of microvascular invasion was 33.1% (26.8 – 73.1%) in our current cohorts. Assessment of microvascular invasion currently relies on histological examination of surgically resected specimens by pathologists. Subjectivity and sampling error are undoubtedly potential problems in evaluating microvascular invasion. Serum tumour markers, pre-operative imaging and gene signatures have been investigated as possible approaches to prediction of microvascular invasion but none has yet been validated and they are not routinely applicable in daily clinical practice.(27) Histological classifications of microvascular invasion have been proposed but none of them are universally accepted and their clinical significance has yet to be validated.(28-30) Hence, for simplicity and better acceptance, only the presence/absence of microvascular invasion was used in the ERASL-post model. Other parameters that might influence RFS could be added to our models although it is evident that extent of surgical resection, resection margin and degree of blood

loss did not emerge as independent prognostic variables. Nonetheless, the models give strikingly clear-cut risk groups and show very similar results within each of the validation sets. Adding more prognostic variables is unlikely to improve our models' performance significantly other than further narrowing the current confidence intervals.

Liver (dys)function is another independent prognosticator to predict tumour recurrence used in ERASL, SLICER and SS-CLIP models.(8, 16) To evaluate liver dysfunction, our ERASL models used ALBI grade, whereas the latter two models used Child-Pugh grade. The ALBI grade is our recently proposed, widely-validated and evidence-based refinement of the Child-Pugh grade. (19, 31) The majority of surgically treated HCC patients belong to Child-Pugh A, which accounted for more than 95% of patients in our current dataset and SLICER and SS-CLIP and Korean cohorts, respectively.(8, 9, 16) We previously demonstrated that Child-Pugh A patients were composed of two prognostically distinct subgroups as classified by the ALBI grade.(4, 19) Therefore, ALBI grade rather than Child-Pugh grade was incorporated in our ERASL models to provide better discriminatory power. However, the underlying reason of the association between liver dysfunction and early recurrence remains unclear.

Tumour recurrence may represent either intrahepatic metastases or development of de-novo tumours. Time of recurrence is one of the factors that has been proposed to distinguish these two entities,(32, 33) although the exact differentiation requires assessment of recurrence clonality by genetic/genomic analyses.(34, 35) Early recurrence is generally believed to represent pre-existing intrahepatic metastasis, whereas late recurrence is regarded as *de-novo* tumour. A cut-off of 2 years has been generally adopted to classify early and late recurrence.(6) Our findings echo other studies in that early and late tumour recurrence are two distinct entities associated with different risk factors.(7, 32, 36) Early recurrence is mainly

determined by aggressive characteristics of the primary (resected) tumour such as tumour size, tumour multiplicity, vascular invasion and higher serum AFP level. These associations support the contention that early recurrence is likely to result from intrahepatic metastasis disseminated from the primary tumour. In contrast, late relapse is primarily associated with aetiology and cirrhotic background, which are well-established risk factors of hepatocarcinogenesis and provide fertile soil for development of de-novo tumours.(2, 6, 37)

There are limitations to our study. Our models, at first sight, may appear complex and difficult to apply at the bedside, but our simple online calculator overcomes this problem. The online calculators, by providing a quantitative measure of recurrence risk at any post-operative time point, are an important step in our ultimate goal of providing personalized prognostication. Antiviral treatment has not been included in our models because it was not recorded in all of our cohorts. However, although the use of antiviral treatment for hepatitis B-related HCC has been consistently shown to improve overall survival, its effect on post-operative recurrence prevention is still inconclusive.(38-40) Reduction of tumour recurrence by antiviral agents on hepatitis C-related HCC is also controversial.(41, 42) Third, tumour size and number were measured radiologically or pathologically in different centres. Although there might be some variations in tumour size depending on the method of assessment, the discrepancies are unlikely to be clinically significant.

In summary, tumour recurrence after curative surgery for HCC is a serious and common complication. Our ERASL models are clinically relevant, externally validated and offer powerful tools to predict early recurrence. Further prospective studies are required to explore the clinical applicability of ERASL models in patient allocation for more frequent follow-up and clinical trials for adjuvant therapy. We are currently developing a more general

prognostic model that is applicable to both early and late recurrence, and the performance of the ERASL models is being prospectively evaluated in an adjuvant clinical trial.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. In: International Agency for Research on Cancer, Lyon, France.

2. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.

3. Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl 2013;19:411-419.

4. Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 2016;114:744-750.

5. Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M, Ercolani G, Cescon M, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009;16:413-422.

6. European Association for the Study of the Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.

7. Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, Chan HL, et al. Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Ann Surg Oncol 2015;22:4138-4148.

8. Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, et al. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One 2015;10:e0118658.

9. Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015;261:939-946.

10. Meniconi RL, Komatsu S, Perdigao F, Boelle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 2015;157:454-462.

11. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-955.

12. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-1354.

13. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 2010;40:943-953.

14. Wang H, Liu A, Bo W, Feng X, Hu Y, Tian L, Zhang H, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Dig Liver Dis 2016;48:1275-1282.

15. Ferrer-Fabrega J, Forner A, Liccioni A, Miquel R, Molina V, Navasa M, Fondevila C, et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016;63:839-849.

16. Huang S, Huang GQ, Zhu GQ, Liu WY, You J, Shi KQ, Wang XB, et al. Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. PLoS One 2015;10:e0129000.

17. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594.

18. Cucchetti A, Mazzaferro V, Pinna AD, Sposito C, Golfieri R, Serra C, Spreafico C, et al. Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. Br J Surg 2017.

19. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.

20. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013;13:33.

21. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-138.

22. Rahman MS, Ambler G, Choodari-Oskooei B, Omar RZ. Review and evaluation of performance measures for survival prediction models in external validation settings. BMC Med Res Methodol 2017;17:60.

23. Stone CJ. The use of polynomial splines and their tensor products in multivariate function estimation. The Annals of Statistics 1994:118-171.

24. Kooperberg C, Stone CJ, Truong YK. Hazard regression. Journal of the American Statistical Association 1995;90:78-94.

25. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine 1996;15:361-387.

26. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, Larson JJ, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 2012;56:614-621.

27. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2017.

28. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375-1382.

29. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009;137:850-855.

30. Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 2016;22:9279-9287.

31. Chan AW, Chan RC, Wong GL, Wong VW, Choi PC, Chan HL, To KF. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. J Gastroenterol Hepatol 2015;30:1391-1396.

32. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507.

33. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, et al. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg 2008;12:1540-1547.

34. Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003;39:215-221.

35. Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, et al. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol 2017;66:363-373.

36. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.

37. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg 2015;261:513-520.

38. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647-3655.

39. Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee KF, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther 2015;41:199-208.

40. Sakamoto K, Beppu T, Hayashi H, Nakagawa S, Okabe H, Nitta H, Imai K, et al. Antiviral therapy and long-term outcome for hepatitis B virus-related hepatocellular

carcinoma after curative liver resection in a Japanese cohort. Anticancer Res 2015;35:1647-1655.

41. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-733.

42. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-168.

Figure legends

Fig. 1. Recurrence-free survival (RFS) according to risk groups defined by the ERASL-pre model. Kaplan-Meier plots for RFS in the low, intermediate and high risk groups of the ERASL-pre model in each of (A) Hong Kong (derivation), (B) Hong Kong (internal validation), (C) Japan, (D) the United States, (E) China and (F) Italy cohorts. Median RFS, hazard ratios (with p-values) and percentage RFS at two years, are reported in Table 3.

Fig. 1. Recurrence-free survival (RFS) according to risk groups defined by the ERASL-post model. Kaplan-Meier plots for RFS in the low, intermediate and high risk groups of the ERASL-post model in each of (A) Hong Kong (derivation), (B) Hong Kong (internal validation), (C) Japan, (D) the United States, (E) China and (F) Italy cohorts. Median RFS, hazard ratios (with p-values) and percentage RFS at two years, are reported in Table 4.

Fig. 3. Calibration plots for the ERASL-pre and ERASL-post models in predicting 2-year recurrence-free survival (RFS). (A, B) Hong Kong (derivation) cohort and (C, D) Hong Kong (internal validation) cohort. Thick dashed line: observed, solid thin line: optimism corrected.

Table 1: Baseline characteristics of patients.

Variables	Derivation cohort		Validation cohorts				
	Hong Kong n=451	**Hong Kong n=130**	**Japan n=615**	**The United States n=661**	**Wenzhou, China n=100**	**Nanning, China n=1204**	**Italy n=742**
Patient factors/Laboratory parameters							
Male gender, n(%)	387 (85.8)	107 (82.3)	469 (76.3)	517 (78.2)	86 (86.0)	1042 (86.5)	578 (77.9), n=742
Age [years, mean (SD)]	56 (10.7), n=451	60 (9.2), n=130	66 (9.3), n=615	60 (11.7), n=661	56 (10.9), n=100	49 (11.4), n=1204	66 (9.1), n=742
Etiology	n=451	n=130	n=614	n=661	n=100	n=1204	n=742
Hepatitis B	380 (84.3)	107 (82.3)	126 (20.5)	286 (43.3)	89 (89.0)	1026 (85.2)	154 (20.8)
Hepatitis C	18 (4.0)	10 (7.7)	362 (59.0)	217 (32.8)	1 (1.0)	12 (1.0)	408 (55.0)
Other	53 (11.8)	13 (10.0)	126 (20.5)	158 (23.9)	10 (10.0)	166 (13.8)	180 (24.3)
Child-Pugh grade, n(%)	n=451	n=130	n=612	n=624	n=100	n=1204	n=742
A	442 (98.0)	127 (97.7)	577 (94.3)	590 (94.6)	63 (63.0)	1154 (95.9)	697 (93.9)
B	9 (2.0)	3 (2.3)	35 (5.7)	34 (5.5)	35 (35.0)	50 (4.2)	45 (6.1)
C	0 (0)	0 (0)	0 (0)	0 (0)	2 (2.0)	0 (0)	0 (0)
ALBI grade, n(%)	n=451	n=130	n=612	n=622	n=100	n=1204	n=742
1	329 (73.0)	99 (76.2)	356 (58.2)	409 (65.8)	51 (51.0)	829 (68.9)	396 (53.4)
2	119 (26.4)	30 (23.1)	253 (41.3)	197 (31.7)	45 (45.0)	373 (31.0)	338 (45.6)
3	3 (0.7)	1 (0.8)	3 (0.5)	16 (2.6)	4 (4.0)	2 (0.2)	8 (1.1)
Albumin [g/L, mean (SD)]	40 (4.4), n=451	41 (4.5), n=130	40 (4.9), n=612	40 (5.7), n=623	39 (5.9), n=100	41 (4.4), n=1204	40 (5.2), n=742
Bilirubin [μmol/L, median (IQR)]	10 (7, 13), n=451	9 (7, 13), n=130	12.0 (9, 15), n=613	12 (9, 15), n=626	14 (10, 18), n=100	12 (9, 16), n=1204	15 (12, 22), n=742
AFP [μg/L, median (IQR)]	52.1 (5.4, 585.0), n=451	20.0 (4.0, 411.0), n=130	13.0 (5.0, 93.0), n=607	45.5 (7.1, 756.0), n=564	175.6 (7.2, 768.8), n=100	139.0 (10.2, 539.7), n=1204	12.3 (4.6, 70.0), n=742
Tumor characteristics							
Tumor size [mm, median (IQR)]	40 (25-60), n=451	30 (20, 55), n=130	28 (18, 44), n=609	50 (30, 85), n=651	50 (30, 70), n=100	60 (40, 98), n=1204	35 (23, 50), n=742
Solitary tumor, n(%)	350 (77.6), n=451	95 (73.1), n=130	489 (80.2), n=610	514 (78.5), n=655	84 (85.7), n=98	885 (71.3), n=1199	573 (77.2), n=742
Tumor differentiation	n=451	n=130	n=599	n=618	n=100	Not available	n=582
Well	76 (16.9)	21 (16.2)	146 (24.4)	134 (21.7)	18 (18.0)	Not available	79 (13.6)
Moderate	318 (70.5)	91 (70.0)	408 (68.1)	318 (51.5)	55 (55.0)	Not available	257 (44.2)
Poor	57 (12.6)	18 (13.9)	45 (7.5)	166 (26.9)	27 (27.0)	Not available	246 (42.3)
Microvascular invasion	121 (26.8), n=451	38 (29.3), n=130	166 (27.7), n=599	476 (73.1), n=651	48.0 (48.0), n=100	Not available	366 (49.3), n=742
Macrovascular invasion	38 (8.4), n=451	9 (6.9), n=130	44 (7.4), n=599	186 (28.6), n=651	9 (9.0), n=100	205 (17.0), n=1203	0 (0), n=742
Clinical outcome							
Recurrence with 2 years, n(%)	162 (35.9), n=451	43 (33.1), n=130	245 (40.0), n=613	284 (43.0), n=661	30 (30.0), n=100	511 (42.4), n=1204	295 (39.8), n=742
Recurrence-free survival, months (95% CI)	66.7 (48.0, 83.1), n=451	Not reached, n=130	27.6 (24.0, 33.8), n=611	21.8 (18.2, 27.9), n=660	Not reached, n=100	11.0 (10.0, 13.0), n=1204	27.7 (24.1, 32.6), n=742

AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; CI, confidence interval; IQR, interquartile range; RFS, recurrence-free survival; SD, standard deviation. Mean (standard deviation) presented for normally distributed continuous variables, while median (interquartile range) was given to those with non-normally distributed continuous variable.

Table 2: Multivariable Cox regression analyses of prognostic factors in the derivation cohort

Variable		ERASL-pre			ERASL-post		
		Hazard ratio (95% C.I.)	**β-estimate (95% C.I.)**	**P-value***	**Hazard ratio (95% C.I.)**	**β-estimate (95% C.I.)**	**P-value***
Gender							
	Female	ref	Ref		ref	ref	
	Male	2.265 (1.305, 3.932)	0.818 (0.266, 1.369)	0.004	1.969 (1.128, 3.434)	0.677 (0.121, 1.234)	0.017
ALBI grade							
	1	ref	Ref		ref	ref	
	2 or 3	1.563 (1.128, 2.166)	0.447 (0.121, 0.773)	0.007	1.581 (1.142, 2.190)	0.458 (0.133, 0.784)	0.006
Microvascular invasion							
	No	Not applicable	Not applicable	NA	ref	ref	
	Yes	Not applicable	Not applicable	NA	1.938 (1.353, 2.775)	0.661 (0.302, 1.021)	<0.0001
ln(AFP)		1.106 (1.053, 1.161)	0.100 (0.052, 0.149)	<0.0001	1.086 (1.033, 1.141)	0.082 (0.032, 0.132)	0.001
ln(Tumor size)		1.785 (1.374, 2.320)	0.580 (0.318, 0.841)	<0.0001	1.570 (1.202, 2.052)	0.451 (0.184, 0.719)	0.001
Tumor number (1 vs 2/3 vs >3)		1.636 (1.350, 1.983)	0.492 (0.300, 0.685)	<0.0001	1.461 (1.194, 1.789)	0.379 (0.177, 0.582)	<0.0001

ERASL-pre score *= 0.818 x Gender (0: Female, 1: Male) + 0.447 x Albumin-Bilirubin (ALBI) grade (0: Grade 1; 1: Grade 2 or 3) + 0.100 x ln(Serum AFP in µg/L) + 0.580 x ln(Tumor size in cm) + 0.492 x Tumor number (0: Single; 1: Two or three; 2: Four or more)*
Cut-offs to generate the risk groups: ≤2.558 (low), >2.558 to ≤3.521 (intermediate), >3.521 (high)

ERASL-post score *= 0.677 x Gender (0: Female, 1: Male) + 0.458 x Albumin-Bilirubin (ALBI) grade (0: Grade 1; 1: Grade 2 or 3) + 0.661 x microvascular invasion (0: no, 1: yes) + 0.082 x ln(Serum AFP in µg/L) + 0.451 x ln(Tumor size in cm) + 0.379 x Tumor number (0: Single; 1: Two or three; 2: Four or more)*
Cut-offs to generate the risk groups: ≤2.332 (low), >2.332 to ≤3.445 (intermediate), >3.445 (high)

AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; CI, confidence interval. *Wald test

Table 3: Median recurrence-free survival (RFS), hazard ratio and 2-year RFS according to each risk group as defined by ERASL-pre model

Cohort	Group	n	Median recurrence-free survival, months (95% C.I.)	Hazard ratio (95% C.I.)	P-value*	2-year RFS, % (95% CI)
Hong Kong (derivation set)	Low	226	84.90 (71.00, not reached)	1		76.34 (70.14, 81.42)
	Intermediate	158	68.20 (23.20, 102.90)	2.05 (1.42, 2.96)	<0.0001	57.36 (49.04, 64.82)
	High	67	7.80 (4.90, 11.80)	5.63 (3.78, 8.40)	<0.0001	29.46 (18.95, 40.74)
Hong Kong (validation set)	Low	76	Not reached	1		77.09 (65.70, 85.12)
	Intermediate	35	33.40 (18.40, not reached)	1.48 (0.69, 3.16)	0.313	67.46 (48.95, 80.50)
	High	19	6.20 (4.20, 11.30)	6.51 (3.22, 13.19)	<0.0001	19.74 (5.51, 40.32)
Japan	Low	404	36.00 (31.20, 48.00)	1		62.52 (57.15, 67.42)
	Intermediate	158	18.00 (14.40, 24.00)	2.03 (1.55, 2.67)	<0.0001	39.73 (31.59, 47.74)
	High	34	4.80 (2.40, 14.40)	4.36 (2.79, 6.80)	<0.0001	19.87 (7.44, 36.61)
U.S.	Low	242	41.86 (30.00, 54.86)	1		64.66 (57.65, 70.80)
	Intermediate	214	15.31 (12.42, 20.80)	2.08 (1.54, 2.80)	<0.0001	41.59 (34.17, 48.83)
	High	93	5.45 (4.24, 10.64)	4.20 (2.95, 5.99)	<0.0001	25.66 (15.87, 36.61)
China (Nanning and Wenzhou)	Low	366	41.00 (30.00, 50.00)	1		60.86 (53.26, 67.61)
	Intermediate	687	12.53 (10.00, 15.00)	2.21 (1.72, 2.83)	<0.0001	34.88 (30.06, 39.74)
	High	244	4.00 (4.00, 5.00)	4.43 (3.38, 5.82)	<0.0001	13.55 (8.52, 19.74)
Italy	Low	421	36.15 (30.76, 44.70)	1		60.51 (55.22, 65.37)
	Intermediate	284	23.16 (19.11, 25.59)	1.53 (1.21, 1.93)	<0.0001	47.20 (40.74, 53.38)
	High	37	11.22 (4.51, 18.09)	2.71 (1.68, 4.37)	<0.0001	31.77 (15.47, 49.44)
All	Low	1735	45.76 (40.79, 49.20)	1		64.82 (62.23, 67.28)
	Intermediate	1536	18.00 (16.30, 20.60)	2.07 (1.85, 2.33)	<0.0001	42.46 (39.56, 45.33)
	High	494	5.45 (4.80, 6.41)	4.67 (4.05, 5.38)	<0.0001	20.70 (16.67, 25.04)

CI, confidence interval. *Wald test

Table 4: Median recurrence-free survival (RFS), hazard ratio and 2-year RFS according to each risk group as defined by ERASL-post model

Cohort	Group	n	Median recurrence-free survival, months (95% C.I.)	Hazard ratio (95% C.I.)	P-value*	2-year RFS, % (95% C.I.)
Hong Kong (derivation set)	Low	226	102.90 (78.90, not reached)	1		80.87 (75.02, 85.49)
	Intermediate	158	25.70 (18.60, 72.50)	3.11 (2.13, 4.55)	<0.0001	50.89 (42.58, 58.61)
	High	67	9.00 (5.70, 12.60)	6.79 (4.47, 10.33)	<0.0001	29.85 (19.44, 40.97)
Hong Kong (validation set)	Low	76	Not reached	1		82.38 (71.55, 89.39)
	Intermediate	36	27.80 (13.20, not reached)	3.00 (1.44, 6.23)	0.003	54.90 (37.16, 69.54)
	High	18	6.20 (4.40, 11.30)	8.45 (3.93, 18.17)	<0.0001	18.52 (3.98, 41.40)
Japan	Low	369	37.20 (31.22, 48.00)	1		63.28 (57.67, 68.35)
	Intermediate	167	20.40 (16.80, 25.20)	1.89 (1.43, 2.49)	<0.0001	42.17 (34.09, 50.01)
	High	46	6.00 (3.60, 14.40)	4.78 (3.24, 7.05)	<0.0001	16.73 (6.89, 30.26)
U.S.	Low	154	70.80 (42.45, 108.62)	1		73.55 (65.21, 80.20)
	Intermediate	275	18.30 (15.31, 25.69)	2.69 (1.86, 3.90)	<0.0001	44.94 (38.31, 51.33)
	High	119	6.37 (4.50, 8.61)	6.09 (4.05, 9.18)	<0.0001	25.91 (16.91, 35.85)
China (Wenzhou only)	Low	31	Not reached	1		87.10 (69.19, 94.95)
	Intermediate	55	60.83 (34.13, not reached)	2.65 (0.89, 7.89)	0.079	68.87 (54.78, 79.37)
	High	12	9.47 (6.77, not reached)	6.91 (2.02, 23.66)	0.002	40.00 (13.52, 65.73)
Italy	Low	325	40.46 (33.35, 46.09)	1		66.32 (60.47, 71.51)
	Intermediate	366	21.88 (17.47, 24.57)	1.86 (1.45, 2.39)	<0.0001	45.98 (40.28, 51.49)
	High	51	11.78 (8.03, 19.11)	3.31 (2.16, 5.07)	<0.0001	29.23 (15.27, 44.71)
All	Low	1181	54.30 (48.00, 64.50)	1		71.03 (68.18, 73.67)
	Intermediate	1057	22.57 (19.84, 24.57)	2.18 (1.89, 2.51)	<0.0001	47.51 (44.23, 50.72)
	High	313	8.10 (6.41, 10.30)	4.92 (4.11, 5.90)	<0.0001	26.10 (20.77, 31.72)

CI, confidence interval. *Wald test

Table 5: Prognostic performance of the ERASL models.

Measure of discrimination	Cohort	ERASL-pre (SE)	ERASL-post (SE)	AJCC TNM (SE)	Korean (SE)	SLICER (SE)
*Harrell's c-index	Hong Kong (Derivation)	0.713 (0.021)	0.735 (0.020)	0.693 (0.018)	0.627 (0.023)	0.716 (0.023)
	Hong Kong (Validation)	0.708 (0.043)	0.723 (0.043)	0.685 (0.039)	0.642 (0.090)	0.717 (0.045)
	Japan	0.656 (0.018)	0.668 (0.018)			
	U.S.	0.669 (0.019)	0.698 (0.018)			
	China	0.672 (0.012)	0.725 (0.056)			
	Italy	0.601 (0.016)	0.616 (0.016)			
*Gönen & Heller's K	Hong Kong (Derivation)	0.689 (0.015)	0.695 (0.014)	0.638 (0.012)	0.599 (0.017)	0.667 (0.014)
	Hong Kong (Validation)	0.692 (0.027)	0.693 (0.027)	0.654 (0.025)	0.614 (0.031)	0.695 (0.028)
	Japan	0.631 (0.016)	0.640 (0.016)			
	U.S.	0.645 (0.017)	0.668 (0.017)			
	China	0.645 (0.010)	0.695 (0.047)			
	Italy	0.599 (0.016)	0.616 (0.015)			
*Royston-Sauerbrei's R^2_D	Hong Kong (Derivation)	0.316 (0.050)	0.354 (0.050)	0.290 (0.050)	0.093 (0.062)	0.270 (0.051)
	Hong Kong (Validation)	0.365 (0.102)	0.388 (0.102)	0.300 (0.098)	0.138 (0.116)	0.320 (0.092)
	Japan	0.154 (0.034)	0.182 (0.040)			
	U.S.	0.177 (0.040)	0.225 (0.042)			
	China	0.166 (0.025)	0.313 (0.128)			
	Italy	0.076 (0.025)	0.104 (0.029)			
^tdAUC (2 years)	Hong Kong (Derivation)	0.736 (0.025)	0.763 (0.023)	0.709 (0.023)	0.644 (0.028)	0.740 (0.025)
	Hong Kong (Validation)	0.745 (0.049)	0.755 (0.049)	0.699 (0.050)	0.673 (0.054)	0.726 (0.053)
	Japan	0.661 (0.025)	0.680 (0.024)			
	U.S.	0.682 (0.026)	0.718 (0.025)			
	China	0.692 (0.022)	0.750 (0.058)			
	Italy	0.614 (0.023)	0.653 (0.023)			

Standard errors (SE) were estimated from 200 bootstrap samples* or from the iid-representation of the estimator^. tdAUC, areas under time-dependent receiver operating characteristic curve

AJCC TNM, American Joint Committee on Cancer Tumor-Node-Metastasis; ERASL, Early Recurrence After Surgery for Liver tumor; SLICER, Singapore Liver Cancer Recurrence; tdAUC, areas under time-dependent receiver operating characteristic curve

Figure

FIGURE 1



FIGURE 2


ERASL-post
A
Hong Kong (derivation set)
B
Hong Kong (validation set)
C
Japan
D
U.S.
E
China (Wenzhou)
F
Italy
1.00
0.75
0.50
0.25
0.00
0
5
10
15
20
25
Recurrence-free survival (months)
low
intermediate
high

FIGURE 3


Hong Kong derivation set (ERASL-pre)
A
Hong Kong derivation set (ERASL-post)
B
Hong Kong validation set (ERASL-pre)
C
Hong Kong validation set (ERASL-post)
D
Observed 2-year recurrence-free survival
Predicted 2-year recurrence-free survival
0.0
0.2
0.4
0.6
0.8
1.0

*Graphical Abstract



Highlights:

- Recurrence is frequent within two years of surgical resection of hepatocellular carcinoma.
- In this large international collaboration, we identify readily available, clinical parameters which influence such recurrence.
- A simple and extensively validated statistical model that permits the risk of early recurrence to be estimated, is presented in the form of an online calculator.
- This facility will enhance patient counselling about the likely success of the treatment and will help in design of adjuvant clinical trials.

Supplementary material

Click here to download Supplementary material: Supplementary data.docx

***ICMJE disclosure form _ Zhong**

Click here to download ICMJE disclosure form: coi_disclosure_zhong.pdf

***ICMJE disclosure form _ Berhane**

Click here to download ICMJE disclosure form: coi_disclosure_berhane.pdf

***ICMJE disclosure form _ Toyoda**

Click here to download ICMJE disclosure form: coi_disclosure_toyoda.pdf

***ICMJE disclosure form _ Chan**

Click here to download ICMJE disclosure form: coi_disclosure_chan.pdf

***ICMJE disclosure form _ cucchetti**

Click here to download ICMJE disclosure form: coi_disclosure_cucchetti.pdf

***ICMJE disclosure form _ shi**

Click here to download ICMJE disclosure form: coi_disclosure_shi.pdf

***ICMJE disclosure form _ tada**

Click here to download ICMJE disclosure form: coi_disclosure_tada.pdf

***ICMJE disclosure form _ chong**

Click here to download ICMJE disclosure form: coi_disclosure_chong.pdf

***ICMJE disclosure form _ xiang**

Click here to download ICMJE disclosure form: coi_disclosure_xiang.pdf

***ICMJE disclosure form _ li**

Click here to download ICMJE disclosure form: coi_disclosure_li.pdf

***ICMJE disclosure form _ lai**

Click here to download ICMJE disclosure form: coi_disclosure_lai.pdf

***ICMJE disclosure form _ mazzaferro**

Click here to download ICMJE disclosure form: coi_disclosure_mazzaferro.pdf

***ICMJE disclosure form _ garciafinana**

Click here to download ICMJE disclosure form: coi_disclosure_GarcaFiana.pdf

***ICMJE disclosure form _ kudo**

Click here to download ICMJE disclosure form: coi_disclosure_kudo.pdf

***ICMJE disclosure form _ kumada**

Click here to download ICMJE disclosure form: coi_disclosure_kumada.pdf

***ICMJE disclosure form _ roayaie**

Click here to download ICMJE disclosure form: coi_disclosure_roayaie.pdf

***ICMJE disclosure form _ johnson**

Click here to download ICMJE disclosure form: coi_disclosure_johnson.pdf